NVAX logo

Novavax (NVAX) Accounts Payable

Annual Accounts Payable

$132.61 M
-$83.91 M-38.75%

December 31, 2023


Summary


Performance

NVAX Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNVAXbalance sheetmetrics:

Quarterly Accounts Payable

$57.52 M
-$22.45 M-28.07%

September 30, 2024


Summary


Performance

NVAX Quarterly Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNVAXbalance sheetmetrics:

Accounts Payable Formula

Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers

NVAX Accounts Payable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-38.8%-43.6%
3 y3 years+144.1%-54.7%
5 y5 years+1325.8%+2184.2%

NVAX Accounts Payable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-38.8%+4.4%-85.1%at low
5 y5-year-38.8%+4457.0%-85.1%+2184.2%
alltimeall time-38.8%>+9999.0%-85.1%>+9999.0%

Novavax Accounts Payable History

DateAnnualQuarterly
Sep 2024
-
$57.52 M(-28.1%)
Jun 2024
-
$79.96 M(+38.5%)
Mar 2024
-
$57.72 M(-56.5%)
Dec 2023
$132.61 M(-38.8%)
$132.61 M(+30.1%)
Sep 2023
-
$101.91 M(+16.8%)
Jun 2023
-
$87.25 M(-30.1%)
Mar 2023
-
$124.80 M(-42.4%)
Dec 2022
$216.52 M(+70.4%)
$216.52 M(+49.3%)
Sep 2022
-
$145.00 M(-62.5%)
Jun 2022
-
$386.49 M(+186.0%)
Mar 2022
-
$135.13 M(+6.4%)
Dec 2021
$127.05 M(+133.8%)
$127.05 M(+113.3%)
Sep 2021
-
$59.56 M(-19.5%)
Jun 2021
-
$74.00 M(-34.9%)
Mar 2021
-
$113.61 M(+109.1%)
Dec 2020
$54.33 M(+1767.1%)
$54.33 M(+259.9%)
Sep 2020
-
$15.10 M(+63.4%)
Jun 2020
-
$9.24 M(+267.0%)
Mar 2020
-
$2.52 M(-13.5%)
Dec 2019
$2.91 M(-68.7%)
$2.91 M(-30.9%)
Sep 2019
-
$4.21 M(-2.2%)
Jun 2019
-
$4.30 M(-30.0%)
Mar 2019
-
$6.15 M(-33.9%)
Dec 2018
$9.30 M(+65.7%)
$9.30 M(+37.0%)
Sep 2018
-
$6.79 M(+1.6%)
Jun 2018
-
$6.69 M(+15.9%)
Mar 2018
-
$5.77 M(+2.8%)
Dec 2017
$5.61 M(-1.3%)
$5.61 M(+7.1%)
Sep 2017
-
$5.24 M(-34.6%)
Jun 2017
-
$8.02 M(+111.6%)
Mar 2017
-
$3.79 M(-33.3%)
Dec 2016
$5.68 M(-52.2%)
$5.68 M(-65.0%)
Sep 2016
-
$16.23 M(+1.5%)
Jun 2016
-
$15.99 M(+42.3%)
Mar 2016
-
$11.24 M(-5.5%)
Dec 2015
$11.89 M(-7.9%)
$11.89 M(+45.0%)
Sep 2015
-
$8.20 M(+15.2%)
Jun 2015
-
$7.12 M(-26.9%)
Mar 2015
-
$9.74 M(-24.5%)
Dec 2014
$12.91 M(+115.7%)
$12.91 M(+333.9%)
Sep 2014
-
$2.98 M(-33.8%)
Jun 2014
-
$4.50 M(+11.9%)
Mar 2014
-
$4.02 M(-32.9%)
Dec 2013
$5.99 M(+85.4%)
$5.99 M(+79.2%)
Sep 2013
-
$3.34 M(+13.3%)
Jun 2013
-
$2.95 M(+35.6%)
Mar 2013
-
$2.17 M(-32.7%)
Dec 2012
$3.23 M(+22.0%)
$3.23 M(+46.5%)
Sep 2012
-
$2.20 M(-34.8%)
Jun 2012
-
$3.38 M(+14.2%)
Mar 2012
-
$2.96 M(+11.9%)
Dec 2011
$2.65 M(-26.0%)
$2.65 M(+10.4%)
Sep 2011
-
$2.40 M(-19.1%)
Jun 2011
-
$2.96 M(-11.9%)
Mar 2011
-
$3.36 M(-5.9%)
Dec 2010
$3.57 M
$3.57 M(+6.6%)
Sep 2010
-
$3.35 M(-2.4%)
DateAnnualQuarterly
Jun 2010
-
$3.43 M(-37.3%)
Mar 2010
-
$5.47 M(+160.9%)
Dec 2009
$2.10 M(+19.9%)
$2.10 M(+35.9%)
Sep 2009
-
$1.54 M(+5.8%)
Jun 2009
-
$1.46 M(+42.6%)
Mar 2009
-
$1.02 M(-41.5%)
Dec 2008
$1.75 M(+17.4%)
$1.75 M(-11.0%)
Sep 2008
-
$1.97 M(+169.8%)
Jun 2008
-
$729.00 K(-66.7%)
Mar 2008
-
$2.19 M(+46.7%)
Dec 2007
$1.49 M(-2.6%)
$1.49 M(-36.8%)
Sep 2007
-
$2.36 M(-4.8%)
Jun 2007
-
$2.48 M(+40.5%)
Mar 2007
-
$1.76 M(+15.3%)
Dec 2006
$1.53 M(+7.3%)
$1.53 M(+73.1%)
Sep 2006
-
$884.00 K(+13.3%)
Jun 2006
-
$780.00 K(-3.8%)
Mar 2006
-
$811.00 K(-43.1%)
Dec 2005
$1.43 M(-56.0%)
$1.43 M(+89.4%)
Sep 2005
-
$753.00 K(-38.8%)
Jun 2005
-
$1.23 M(-19.0%)
Mar 2005
-
$1.52 M(-53.2%)
Dec 2004
$3.24 M(+38.4%)
$3.24 M(-21.2%)
Sep 2004
-
$4.11 M(+1.4%)
Jun 2004
-
$4.06 M(+71.7%)
Mar 2004
-
$2.36 M(+0.9%)
Dec 2003
$2.34 M(-7.6%)
$2.34 M(+6.4%)
Sep 2003
-
$2.20 M(+29.9%)
Jun 2003
-
$1.69 M(+5.9%)
Mar 2003
-
$1.60 M(-36.9%)
Dec 2002
$2.53 M(+79.7%)
$2.53 M(-1.9%)
Sep 2002
-
$2.58 M(-40.2%)
Jun 2002
-
$4.32 M(+136.5%)
Mar 2002
-
$1.83 M(+29.5%)
Dec 2001
$1.41 M(+0.6%)
$1.41 M(-4.9%)
Sep 2001
-
$1.48 M(-2.5%)
Jun 2001
-
$1.52 M(+45.1%)
Mar 2001
-
$1.05 M(-25.2%)
Dec 2000
$1.40 M(+180.2%)
$1.40 M(-27.2%)
Sep 2000
-
$1.93 M(+46.8%)
Jun 2000
-
$1.31 M(+113.5%)
Mar 2000
-
$614.00 K(+22.8%)
Dec 1999
$500.00 K(-37.5%)
$500.00 K(-28.6%)
Sep 1999
-
$700.00 K(+250.0%)
Jun 1999
-
$200.00 K(-75.0%)
Mar 1999
-
$800.00 K(0.0%)
Dec 1998
$800.00 K(+300.0%)
$800.00 K(+700.0%)
Sep 1998
-
$100.00 K(-50.0%)
Jun 1998
-
$200.00 K(0.0%)
Mar 1998
-
$200.00 K(0.0%)
Dec 1997
$200.00 K(-50.0%)
$200.00 K(+100.0%)
Sep 1997
-
$100.00 K(-66.7%)
Jun 1997
-
$300.00 K(0.0%)
Mar 1997
-
$300.00 K(-25.0%)
Dec 1996
$400.00 K
$400.00 K(+33.3%)
Sep 1996
-
$300.00 K(-25.0%)
Jun 1996
-
$400.00 K(0.0%)
Mar 1996
-
$400.00 K

FAQ

  • What is Novavax annual accounts payable?
  • What is the all time high annual accounts payable for Novavax?
  • What is Novavax annual accounts payable year-on-year change?
  • What is Novavax quarterly accounts payable?
  • What is the all time high quarterly accounts payable for Novavax?
  • What is Novavax quarterly accounts payable year-on-year change?

What is Novavax annual accounts payable?

The current annual accounts payable of NVAX is $132.61 M

What is the all time high annual accounts payable for Novavax?

Novavax all-time high annual accounts payable is $216.52 M

What is Novavax annual accounts payable year-on-year change?

Over the past year, NVAX annual accounts payable has changed by -$83.91 M (-38.75%)

What is Novavax quarterly accounts payable?

The current quarterly accounts payable of NVAX is $57.52 M

What is the all time high quarterly accounts payable for Novavax?

Novavax all-time high quarterly accounts payable is $386.49 M

What is Novavax quarterly accounts payable year-on-year change?

Over the past year, NVAX quarterly accounts payable has changed by -$44.40 M (-43.56%)